• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹

    4/9/26 8:05:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    New sustainability platform reflects company's commitment to responsible sourcing, more

    efficient manufacturing, and offsetting a portion of plastic footprint
    *†1

    ROCHESTER, N.Y., April 9, 2026 /PRNewswire/ -- CooperVision announced today the launch of its MADE BETTER™ Promise—a new global sustainability platform focused on smarter, more sustainable choices.*†1 Built on years of CooperVision innovation in sustainability, MADE BETTER™ Promise is woven throughout the life of participating products, beginning with the MyDay® daily disposable family of contact lenses.*†1

    COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week, and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. For more information, visit coopervision.com. (PRNewsfoto/CooperVision, Inc.)" alt="CooperVision, a division of CooperCompanies (NASDAQ:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week, and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. For more information, visit coopervision.com. (PRNewsfoto/CooperVision, Inc.)">

    As part of the MADE BETTER™ Promise, CooperVision's MADE BETTER™ Innovation with MyDay® is introducing mindful packaging material choices and manufacturing improvements that lowers the carbon impact.*†1 The company also continues to offset a portion of MyDay® plastic footprint through its plastic neutrality program.†‡2

    Key elements of CooperVision's MADE BETTER™ Innovation include:

    • Use of ISCC PLUS-certified materials in the packaging of participating products, making CooperVision the first and only contact lens manufacturer to do so.*†§♦1,3 The plastic within MyDay® blisters is 100% ISCC PLUS-certified bio-attributed material sourced and allocated via the ISCC mass balance approach.¶3,4
    • Manufacturing processes intentionally designed to reduce carbon footprint through next-generation technologies and improved resource efficiency. *†**††‡‡1,5
    • Use of lower-carbon energy where possible across production operations.§§6
    • Manufacturing sites that recycle more than 90% of waste, helping conserve natural resources.♦♦7

    MADE BETTER™ Innovation also encompasses CooperVision's plastic neutrality program with Plastic Bank, which supports the removal of plastic waste from coastal communities while creating positive socioeconomic impact.†‡2 To date, the program has enabled the collection and recycling of more than 659 million plastic bottles from coastal areas where plastic pollution is prevalent.¶¶8 

    "CooperVision's sustainability progress begins with innovation—in materials, manufacturing, and the way we think about the full life cycle of our products.*†1 MADE BETTER™ Promise reflects how we are turning those innovations into real–world impact through thoughtful choices that benefit both People + Planet,*♦♦♦1,9 said Aldo Zucaro, Senior Director of Corporate Responsibility, CooperCompanies. "We're off to a strong start, delivering practitioners and their patients the same MyDay®—just made with less carbon." ****††††6

    CooperVision's MADE BETTER™ Promise is an ongoing global commitment, with continued advancements in materials, technologies, and processes intended to further reduce environmental impact over time.*1

    *CooperVision's MADE BETTER Innovation program has introduced lower-carbon inputs with traceable sourcing - including ISCC PLUS-certified, lower-carbon plastic and lower-carbon aluminum - into the primary packaging of the MyDay® range of products. It also refers to process improvements that have reduced waste, improved energy efficiency, and lowered greenhouse gas emissions during production of the MyDay® range of products. Methods and verification information are available at [coopervision.com/sustainability/methods].

    †Through its partnership with Plastic Bank, CooperVision offsets a portion of its plastic footprint by funding the collection and recycling of plastic waste, equivalent in weight to the plastic used in participating soft contact lens products sold in participating countries, gathered within 30 miles of oceans or waterways in countries where Plastic Bank operates. Plastic weight is based on the total weight of plastic in the lens, blister, and secondary packaging, including laminates, adhesives, and auxiliary inputs (e.g. ink). This does not include plastic used during the manufacturing process.

    ‡Plastic used in participating CooperVision soft contact lens products is determined by the weight of plastic in the blister, the lens, and the secondary package, including laminates, adhesives, and auxiliary inputs (e.g. ink). The determination does not include plastic used during the manufacturing process for both these products and their packaging.

    §'Packaging' refers to the blister pack that directly encloses each contact lens - the plastic tray sealed with an aluminum foil lid.

    ♦Determination is based on a review of the ISCC PLUS-certified public license database and publicly available information. ISCC PLUS-certified licenses are issued at supplier/site level and may not identify downstream brands. As of November 6, 2025, no other contact lens manufacturers were identified as using ISCC PLUS-certified plastic. ISCC License number ISCC-L-228, valid beginning April 6, 2026, along with CooperVision's internal documentation shows that 100% of the polypropylene used within the MyDay® blisters is ISCC PLUS-certified bio-attributed material sourced and allocated via the mass balance approach; certification does not imply physical segregation.

    ¶Foil lidding atop of the MyDay® blisters and the contact lenses themselves are not ISCC PLUS-certified.

    **Refers to continuous manufacturing improvement processes undertaken by CooperVision to increase efficiency

    ††Carbon footprint is limited to Scope 1 and 2 emissions, defined as: Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from the generation of purchased energy.

    ‡‡CooperVision's 2021 and 2022 Environmental, Social, and Governance Reports.

    §§The MyDay® range of products are manufactured at two facilities that use lower-carbon energy sources. At CooperVision's Juana Díaz, Puerto Rico site, combined heat and power (CHP) technology generates electricity and thermal energy more efficiently than conventional grid-supplied electricity and separate heating systems. Based on CooperVision's scope 1 and scope 2 emissions data, total greenhouse gas emissions per manufactured lens at this facility in 2024 were approximately 30% lower than in 2021, prior to CHP startup. At its manufacturing facilities in the UK, CooperVision purchases 100% renewable energy.

    ♦♦SCS Global Services Certificate No. SCS-ZW-0018 verifies a recycling rate of 94.7% for the Juana Díaz, PR facility. SCS Global Services is an international leader in third-party certification, validation, and verification for environmental sustainability. CooperVision's internal records demonstrate an average recycling rate of over 90% for its MyDay® manufacturing facilities in the UK.

    ¶¶CooperVision, through its collaboration with Plastic Bank, has collected and recycled approximately 12.4M kg of plastic waste gathered within 30 miles of oceans or waterways in countries where Plastic Bank operates as of February 2026. Using Plastic Bank's metric of 1kg of plastic equaling 50 standard 202mm bottles, that will be the equivalent of approximately 659M plastic bottles.

    ♦♦♦As of October 3, 2025, more than 7,000 Plastic Bank collection members across 500+ communities in Indonesia, Egypt, and the Philippines have exchanged collected plastic waste for income and life-improving benefits (such as insurance, digital connectivity, grocery vouchers, and school supplies) through CooperVision's plastic neutrality program with Plastic Bank, cumulative since January 2021.

    ****Results compare 2024 with a 2021 baseline. Full life cycle assessment has been conducted in accordance with ISO 14067 and verified through independent critical review from a cradle-to-grave basis, which covers all product stages from raw material extraction to end-of-life. Details on methodology and verification are available at [coopervision.com/sustainability/methods].

    ††††Carbon reduction' and/or 'lower carbon' refer to a reduction in total greenhouse gas emissions, expressed as carbon dioxide equivalent (CO2e). No carbon offsets are used.

    References:

    1. CVI data on file, 2023-2025
    2. CVI data on file, 2024.
    3. CVI data on file, 2025.
    4. International Sustainability & Carbon Certification, 2025, https://iscc-system.org/about/who-we-are.]
    5. CVI data on file, 2023.
    6. CVI data on file, 2021-2025.
    7. CVI data on file, 2024-2025.
    8. CVI data on file as of 03/2026.
    9. Plastic Bank, CVI data on file, 2025

    SA17810/APP163993

    About CooperVision

    CooperVision, a division of CooperCompanies (NASDAQ:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

    About CooperCompanies

    CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

    Media Contact

    Heather Kowalczyk, APR

    McDougall Communications for CooperVision

    [email protected] or +1.585.434.2148

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/coopervision-launches-made-better-promise-beginning-with-myday-contact-lenses-302737769.html

    SOURCE CooperVision, Inc.

    Get the next $COO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    3/4/2026$85.00Buy → Neutral
    Rothschild & Co Redburn
    2/3/2026$100.00 → $99.00Buy
    Needham
    11/13/2025$72.00Overweight → Equal Weight
    Wells Fargo
    10/13/2025$85.00Overweight
    Barclays
    10/1/2025$64.00Sell
    Goldman
    8/28/2025$72.00Buy → Neutral
    Citigroup
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    More analyst ratings

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cooper downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Cooper from Buy to Neutral and set a new price target of $85.00

    3/4/26 8:35:56 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Needham reiterated coverage on Cooper with a new price target

    Needham reiterated coverage of Cooper with a rating of Buy and set a new price target of $99.00 from $100.00 previously

    2/3/26 7:02:57 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Cooper from Overweight to Equal Weight and set a new price target of $72.00

    11/13/25 8:26:09 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    SEC Filings

    View All

    The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    4/8/26 4:53:52 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by The Cooper Companies Inc.

    SCHEDULE 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    3/26/26 5:42:21 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by The Cooper Companies Inc.

    10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

    3/6/26 4:12:10 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucchese Cynthia L bought $149,963 worth of shares (1,784 units at $84.06), increasing direct ownership by 23% to 9,445 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/23/25 4:08:36 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Rivas Maria bought $82,130 worth of shares (1,000 units at $82.13) (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/19/25 4:18:51 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kurzius Lawrence Erik bought $165,000 worth of shares (2,000 units at $82.50), increasing direct ownership by 35% to 7,777 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    12/17/25 5:06:19 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹

    New sustainability platform reflects company's commitment to responsible sourcing, moreefficient manufacturing, and offsetting a portion of plastic footprint*†1ROCHESTER, N.Y., April 9, 2026 /PRNewswire/ -- CooperVision announced today the launch of its MADE BETTER™ Promise—a new global sustainability platform focused on smarter, more sustainable choices.*†1 Built on years of CooperVision innovation in sustainability, MADE BETTER™ Promise is woven throughout the life of participating products, beginning with the MyDay® daily disposable family of contact lenses.*†1 COO), is one of the world's leading manufacturers of contact l

    4/9/26 8:05:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Telix Strengthens Board with Additional Director Appointments

    MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata

    4/8/26 6:44:20 PM ET
    $ANIK
    $AVNT
    $COO
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

    CooperCompanies Announces First Quarter 2026 Results

    SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We're pleased to report a strong start to the fiscal year, highlighted by product launches,

    3/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Weiss Robert S

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/6/26 5:16:40 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Rivas Maria

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/6/26 5:16:25 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Jay Colleen

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/6/26 5:16:09 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Walter M Rosebrough, Jr. to its Board of Directors

    SAN RAMON, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today that the Company's Board of Directors (the "Board") has appointed Walter (Walt) M Rosebrough, Jr. as an independent director, effective as of January 3, 2026. In connection with this appointment, the Company also has entered into a cooperation agreement (the "Cooperation Agreement") with Browning West, LP. ("Browning West"). Mr. Rosebrough will join the Board's Corporate Governance & Nominating Committee. The Board has also agreed that, by the end of 2026, it shall provide due and serious consideration for Mr. Rosebrough to be appointed Chair of the Board. In

    12/23/25 8:00:00 AM ET
    $COO
    $STE
    $VREX
    Ophthalmic Goods
    Health Care
    Industrial Specialties
    Industrial Machinery/Components

    Browning West Delivers Letter to The Cooper Companies Board of Directors

    Cooper's Lack of Strategic Focus, Misaligned Incentives, and Inadequate Board Oversight Have Led to Meaningful Underperformance Current Corporate Structure Obscures Value of Both CooperVision and CooperSurgical; Refocus as a Pure Play Vision Care Company Under a Refreshed Board May Lead to More Than a Doubling of Cooper's Stock Price Urges Cooper's Board to Appoint Browning West's Highly Skilled Director Candidates Who Will Improve the Company's Operating Plans Including Capital Allocation, Overhaul Management Incentives, and Evaluate Strategic Alternatives for CooperSurgical LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Browning West, LP ("Browning West", "us", or "we"), an investment

    11/19/25 8:45:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Appoints Barbara Carbone to Board of Directors

    SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

    4/30/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces First Quarter 2026 Results

    SAN RAMON, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2026. First quarter 2026 revenue of $1.024 billion, up 6%, or up 3% organically, from last year's first quarter.First quarter 2026 GAAP diluted earnings per share (EPS) of $0.66, up $0.14 or 27% from last year's first quarter.First quarter 2026 Non-GAAP diluted EPS of $1.10, up $0.18 or 20% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We're pleased to report a strong start to the fiscal year, highlighted by product launches,

    3/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for First Quarter 2026

    SAN RAMON, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report first quarter 2026 financial results on Thursday, March 5, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful mo

    2/5/26 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Fourth Quarter and Full Year 2025 Results

    SAN RAMON, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today financial results for its fiscal fourth quarter and full year ended October 31, 2025. Fourth quarter 2025 revenue of $1,065.2 million, up 5%, or up 3% organically. Fiscal year 2025 revenue of $4.1 billion, up 5%, or up 4% organically.Fourth quarter 2025 GAAP diluted earnings per share (EPS) of $0.43, down 27%. Fiscal 2025 GAAP diluted EPS of $1.87, down 4%.Fourth quarter 2025 non-GAAP diluted EPS of $1.15, up 11%. Fiscal 2025 non-GAAP diluted EPS of $4.13, up 12%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. "We closed fis

    12/4/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care